The text presents an overview of Medtronic plc's financial performance and strategic decisions over different time periods, highlighting fluctuations in net sales, operating profit, and income before taxes. It also discusses changes to equity due to stock issuance, repurchases, dividends, and comprehensive income. Additionally, it delves into the classification of assets and liabilities within Level 3 based on fair value measurements, including activities related to different securities, debt obligations, and financial instruments like derivatives. The text further outlines Medtronic's hedging strategies such as cash flow hedges, net investment hedges, and derivative contracts used for managing risks associated with currency exchange and interest rate changes, thereby offering a comprehensive insight into the company's financial health and risk management practices.
The text discusses Medtronic plc's Management's Discussion and Analysis of Financial Condition and Results of Operations, focusing on key points such as the use of non-GAAP financial measures for evaluating operational performance, the impact of the COVID-19 pandemic on global procedural volumes, and financial data on revenue and earnings per share. It provides reconciliations between GAAP and non-GAAP financial measures, details on net sales by segment and geography, and discusses various medical technologies offered by Medtronic including Interventional Lung Solutions, Robotics, Neuroscience, Diabetes, among others. The text further covers specific financial data like costs, expenses, research and development, selling expenses, and how the company strategizes to mitigate the impact of COVID-19 through new product launches and market acceptance plans. Lastly, it outlines the influence of the Enterprise Excellence Program on Medtronic's financials and operational structure, with insights on costs and restructuring charges.
The text discusses the currency exchange rate risk and interest rate risk faced by a company due to its global operations. The company is exposed to fluctuations in earnings and cash flows due to changes in currency exchange rates, and it manages this risk using currency exchange rate derivative instruments. The company's current outstanding notional amount for these contracts is $15.2 billion. A sensitivity analysis shows that a 10% appreciation/depreciation in the U.S. dollar would impact the fair value of these contracts by $1,055 million in either direction. Additionally, the company is exposed to interest rate risk on its investments and borrowings, with a sensitivity analysis indicating a $32 million impact for a hypothetical 10 basis point increase/decrease in interest rates. These risks and their management strategies are further detailed in the company's financial statements and Management's Discussion and Analysis.
Management, along with the CEO and CFO, has assessed the effectiveness of disclosure controls and procedures and any changes in internal control over financial reporting as of the report's end. They have determined that the disclosure controls and procedures are effective, and there have been no significant changes in internal control over financial reporting during the period covered, including impacts from the COVID-19 pandemic.
The text discusses the Securities and Exchange Commission's updated ruling in August 2020 regarding the disclosure threshold for legal proceedings under environmental laws involving governmental authorities. The company has adopted a $1 million threshold for disclosure, deeming matters below this threshold as immaterial. Details of the company's policies on legal proceedings can be found in management's discussion and analysis, and information on legal proceedings and other loss contingencies is outlined in Note 16 of the current financial statements.
I'm ready to provide the summary once you provide the text parts for me to summarize.
The text provides information about the shares repurchased by the Company during the third quarter of fiscal year 2022. The Company repurchased a total of 3,433,500 shares at an average price of $108.14 per share. The repurchases were made as part of a publicly announced program, with a maximum approximate dollar value of $4,350,866,973 for shares that may yet be purchased under the program. Additionally, in March 2019, the Company's Board of Directors authorized the repurchase of $6.0 billion of the Company's ordinary shares with no specific time period associated. During the same quarter, the Board also authorized the redemption of the previously outstanding 1,872 Preferred A Shares for $0.075 million.
I'm here to help! Please go ahead and send me the text that needs to be summarized.
I am ready to help summarize the text for you as soon as you provide the text for me to review.
Medtronic engaged in certain activities in Russia that required disclosures under US law. These activities, authorized by the US Government, involved Medtronic Russia filing notifications with the Federal Security Service (FSB) regarding medical devices using encryption functionality imported into Russia. Although the FSB is on the Specially Designated Nationals List under OFAC, transactions were authorized under Cyber General License No. 1B. While the FSB was later designated for sanctions, previously authorized dealings remained valid. Medtronic filed two notifications with the FSB in Q3 FY22, compliant with Russian law, not generating revenue. Future engagement with the FSB may continue for compliance purposes if permitted under US law.
The text provided includes a list of exhibits related to Medtronic, such as various plans and agreements, certifications of executives under the Sarbanes-Oxley Act, and additional required documents. It ends with a signature and date representing the completion of the report by the official controller and chief accounting officer of Medtronic.
